Israeli companies develop bioprinted organs
Stratasys, CollPlant to first produce breast implants using Stratasys’ P3 bioprinter and CollPlant’s bio-inks derived from collagen, designed to replace silicone implants by regenerating breast tissue without eliciting an immune response
Israel-based Stratasys -- a 3D printing manufacturer, and CollPlant – a regenerative and aesthetic medicine company, announced a joint development of plant-based technologies for tissue regeneration and organ manufacturing.
The initial project of the Rehovot-based companies is to produce breast implants using Stratasys’ P3 bioprinter and CollPlant’s bio-inks derived from collagen. The implants are designed to replace silicone implants by regenerating breast tissue without eliciting an immune response.
Stratasys CEO Yoav Zeif said the partnership with CollPlant “will enable us to accelerate the industrialization of bioprinting for regenerative medicine, and we look forward to the successful commercialization of CollPlant’s novel regenerative breast implants and beyond.”
CollPlant CEO Yehiel Tal said the company is “excited to collaborate on this transformative initiative.”
“We believe that our rhCollagen-based regenerative implant has the potential to overcome the challenges of existing breast procedures that use silicone implants or autologous fat tissue transfer,” he added.
We need more of this kind of biotech. Restoring body parts lost to disease, accident, and trans-mutilation should be the #1 priority. Instead, clown world goes for spike protein clots and stupid fake meat made from cancer cells.